Precision BioSciences jumps after FDA clears trial for muscle‑wasting disease therapy

Precision Biosciences

11/02/2026 12:35

** Shares of drug developer Precision BioSciences DTIL.O rise 6% to $4 premarket

**  Co receives the U.S. FDA's clearance to begin testing its experimental therapy, PBGENE‑DMD, for Duchenne muscular dystrophy, a muscle‑wasting condition that weakens the heart

**  PBGENE‑DMD aims to fix the underlying genetic error with one‑time treatment; pre-clinical data showed restored muscle protein production and improved muscle function, co says

** The early‑to‑mid‑stage study will enroll boys with common DMD mutations at U.S. sites; initial data expected end‑2026 - Co

** Shares rose ~9% in 2025

 (Reporting by Sahil Pandey in Bengaluru)

 ((Sahil.Pandey@thomsonreuters.com))